Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Silver Nanocluster DNA Probes Detect MicroRNA

By LabMedica International staff writers
Posted on 23 Oct 2012
A method that uses inexpensive technology and simple analytical apparatuses promises to trim days off the laboratory work done to diagnose diseases. More...


Any disease that assails a patient leaves genetic clues all over the victim, and because the profiles of micro ribonucleic acid (miRNA) vary by type of cancer, finding it proves beyond a reasonable doubt what is making the patient sick.

A chemist and a biologist from University of Copenhagen (Denmark) invented the detection method, which exploits a natural quality of genetic material. Together they figured out how to attach the light emitting molecules to DNA sensors for miRNA detection. When these luminous DNA-strands stick with microRNA-strands, their light is quenched, giving a very visible indication that the target miRNA is present in the sample.

A single DNA strand is made up of molecules, so called bases, ordered in a unique combination. When two strands join to form their famous double helix, they do so by sticking to complementary copies of themselves. Likewise, strands tailored to match particular miRNAs will stick to the real thing with uncanny precision.

The scientists tested their Silver Nano Cluster DNA probes with eight different types of genetic material and found that they work outright with six of them. They then fathomed how to fix the ones that did not perform. This indicates that their method will work in the detection of almost all types of miRNAs, also in all likelihood for cancer related miRNAs. The most widespread current miRNA detection method requires some 48 hours of laboratory work from raw samples. The new method can do the same job of detection within a maximum of six hours.

Tom Vosch, PhD, from the Department of Chemistry and senior coauthor of the study said, "We invented a probe that emits light only as long as the sample is clean. That is an unusually elegant and easy way to screen for a particular genetic target." The study was published on September 4, 2012, in the American Chemical Society journal ACSNano.

Related Links:

University of Copenhagen



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.